# Optomed Oyj > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/optomed). ## Overview Optomed is a Finnish health technology company specializing in handheld fundus cameras and screening software solutions. The company integrates its devices with software and AI to revolutionize the diagnosis process of diseases like diabetic retinopathy. Optomed operates globally, with offices in Finland, the USA, and China, and distributes its products in over 60 countries. The company is transitioning from innovation-driven development to large-scale commercial deployment, focusing on integrating its technology into primary healthcare settings. ## Products & services • Handheld fundus cameras • Screening software solutions • AI integration for disease diagnosis • Optomed Lumo fundus camera • Clinical screening solutions • Software development for healthcare • Global distribution network - **Fundus Cameras** (50%) — Handheld devices for retinal imaging. - **Screening Software** (30%) — Software solutions for disease screening. - **AI Solutions** (10%) — AI integration for enhanced diagnostic accuracy. - **Clinical Solutions** (10%) — Comprehensive solutions for clinical environments. - Handheld fundus cameras - Screening software solutions - AI integration for disease diagnosis - Optomed Lumo fundus camera - Clinical screening solutions - Software development for healthcare - Global distribution network ## Customers Optomed's customer base primarily includes healthcare providers such as hospitals, clinics, and eye care specialists who require advanced diagnostic tools. The company's products are particularly valuable in primary healthcare settings for early disease detection, especially diabetic retinopathy. Optomed also targets healthcare systems looking to integrate AI-driven solutions for improved diagnostic efficiency. The global reach of Optomed's distribution network allows it to cater to diverse markets, enhancing accessibility to its innovative healthcare solutions. - **Healthcare Providers** (primary) — Hospitals and clinics purchasing diagnostic tools for retinal imaging. - **Eye Care Specialists** (secondary) — Specialists using fundus cameras for detailed eye examinations. - **Healthcare Systems** (emerging) — Systems integrating AI solutions for enhanced diagnostic processes. - Hospitals and clinics seeking advanced diagnostic tools - Eye care specialists focused on retinal imaging - Primary healthcare providers for early disease detection - Healthcare systems integrating AI for diagnostics - Global markets needing accessible healthcare solutions ## Geography Optomed operates internationally, with key offices in Finland, the USA, and China. Its products are distributed in over 60 countries, allowing the company to tap into diverse healthcare markets. The manufacturing of Optomed's devices takes place in Thailand, which is strategically important for cost-effective production. The company's presence in major markets like the USA ensures access to advanced healthcare systems and regulatory environments that support AI-driven diagnostics. - Headquartered in Finland with offices in USA and China - Products distributed in over 60 countries - Manufacturing operations based in Thailand - Key market presence in the USA for advanced healthcare access ## Strategy Optomed's strategic priorities include expanding its market presence by scaling its commercial operations and integrating its technology into primary healthcare. The company focuses on enhancing the usability and connectivity of its devices, exemplified by the launch of the Optomed Lumo camera. Optomed aims to leverage AI to improve diagnostic accuracy and efficiency, positioning itself as a leader in AI-driven healthcare solutions. The company also seeks to strengthen its global distribution network to increase accessibility to its products. - **Commercial Expansion** (medium-term) — To increase market presence and sales. - **AI Integration** (long-term) — To improve diagnostic accuracy and efficiency. - **Product Usability** (short-term) — To enhance user experience and workflow efficiency. - Scaling commercial operations for market expansion - Integrating technology into primary healthcare settings - Enhancing device usability and connectivity - Leveraging AI for improved diagnostic accuracy - Strengthening global distribution network ## Risks Optomed faces several risks including geopolitical tensions that could impact its supply chain and sales competitiveness. The quality and safety of its products are crucial for maintaining market position, and any failure in product development could negatively affect the company. Strategic execution risks exist, as successful implementation depends on factors beyond the company's control. Additionally, Optomed must navigate complex regulatory environments across different countries, which could pose legal and compliance challenges. - **Geopolitical Tensions** [high] — Could disrupt supply chain and increase costs. - **Product Quality** [critical] — Essential for maintaining competitive edge. - **Regulatory Compliance** [high] — Complex international regulations pose challenges. - Geopolitical tensions affecting supply chain and sales - Product quality and safety impacting market competitiveness - Challenges in strategic execution and market adaptation - Regulatory compliance across diverse international markets ## Accounting Optomed's financial statements are prepared in accordance with IFRS, requiring management to make significant judgments and estimates. Revenue recognition is critical, especially with international sales and varying contract terms. The company must carefully manage inventory valuation and impairment assessments due to its global operations. Additionally, Optomed faces challenges in accounting for R&D expenses, which are crucial for its innovation-driven business model. These accounting areas significantly impact the company's reported financial position and performance. - **Revenue Recognition** - **Inventory Valuation** - **R&D Expenses** - Revenue recognition across international markets - Inventory valuation and impairment assessments - R&D expense accounting for innovation activities - Judgments and estimates affecting financial reporting --- *Last updated: 2026-08-11T04:04:55.099410+00:00*